Evidence map›Paper›PMID 40580320›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy.

Wolfgang Roll, Lucas Plagwitz, David Ventura, Max Masthoff, Clemens Backhaus, Julian Varghese, Kambiz Rahbar, Philipp Schindler

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wolfgang Roll *Department of Nuclear Medicine, University Hospital Münster, Münster, Germany. wolfgang.roll@ukmuenster.de.ORCID 0000-0002-3746-9393
Lucas Plagwitz *Institute of Medical Informatics, University of Münster, Münster, Germany.
David VenturaDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Max MasthoffWest German Cancer Centre, Münster, Germany.
Clemens BackhausDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Julian VargheseInstitute of Medical Informatics, University of Münster, Münster, Germany.
Kambiz RahbarDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Philipp SchindlerWest German Cancer Centre, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis retrospective study aims to develop a deep learning-based approach to whole-body CT segmentation out of standard PSMA-PET-CT to assess body composition in metastatic castration resistant prostate cancer (mCRPC) patients prior to [

methodsWe used a deep learning segmentation model to perform fully automated segmentation of different tissue compartments, including visceral- (VAT), subcutaneous- (SAT), intra/intermuscular- adipose tissue (IMAT) from [

resultsThe automated segmentation model was useful for delineating different adipose tissue compartments and skeletal muscle across different patient anatomies. Analyses revealed significant correlations between lower SAT and higher IMAT ratios and poorer therapeutic outcomes in Cox regression analysis (SAT/TAT: p = 0.038; IMAT/TAT: p < 0.001) in the 3D model. In the single slice approach only IMAT/SAT was significantly associated with survival in Cox regression analysis (p < 0.001; SAT/TAT: p > 0.05). IMAT ratio remained an independent predictor of survival in multivariate analysis when including PSMA-PET and blood-based prognostic factors.

conclusionsIn this proof-of-principle study the implementation of a deep learning-based whole-body analysis provides a robust and detailed CT-based assessment of body composition in mCRPC patients undergoing RLT. Potential prognostic parameters have to be corroborated in larger prospective datasets.

Indexed as

Body CompositionGlutamate Carboxypeptidase IIPositron Emission Tomography Computed TomographyProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAntigens, SurfaceDeep LearningHumansMaleMiddle AgedOligopeptidesPrognosisRetrospective StudiesAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIOligopeptidesBody compositionPSMA-PETPSMA-therapy

Identifiers

PMID40580320
PMCPMC12660389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.